Article

Use of a sodium--glucose cotransporter 2 inhibitor, empagliflozin, in a patient with Rabson-Mendehall Syndrome

2021-02-24

Abstract excerpt

Rabson-Mendenhall Syndrome (RMS) is a rare condition caused by mutations in the insulin receptor gene. The affected patients have severe insulin resistance and the treatment is challenging due to difficulties in reaching satisfactory glycemic control. We report a case where iSGT2 was used as an adjunct therapy to insulin.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5742c2a0-36b5-53ac-abfd-98e5a64a268a
DOI: 10.22541/au.161419442.28253349/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Use of a sodium--glucose cotransporter 2 inhibitor, empagliflozin, in a patient with Rabson-Mendehall SyndromeDOI 10.22541/au.161419442.28253349/v1Read

Use of a Sodium-Glucose Cotransporter 2 Inhibitor, Empagliflozin, in a Patient with Rabson-Mendenhall Syndrome.Semantic proximity Read

Management challenges of Rabson Mendenhall syndrome in a resource limited country: a case report.Semantic proximity Read

Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium-glucose cotransporter 2 inhibitor.Semantic proximity Read

Functional characterization of insulin receptor gene mutations contributing to Rabson-Mendenhall syndrome - phenotypic heterogeneity of insulin receptor gene mutations.Semantic proximity Read

Genealogical Rabson-Mendenhall syndrome caused by INSR gene mutation.Semantic proximity Read

Rabson-Mendenhall syndrome with recurrent cerebral infarcts caused by a novel INSR mutation.Semantic proximity Read

Successful rhIGF1 treatment for over 5 years in a patient with severe insulin resistance due to homozygous insulin receptor mutation.Semantic proximity Read

Metreleptin Improves Blood Glucose in Patients With Insulin Receptor MutationsSemantic proximity Read